Bemoradan

This classification denotes a phosphodiesterase inhibitor with the molecular formula C13H13N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G2S2V1ETBQ, chemically known as 7-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)-2h-1,4-benzoxazin-3(4h)-one but generally known as bemoradan, which bears US NIH Compound Identifier 5362399. European Medicines Agency schedules Bemoradan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05695MIG. The term BEMORADAN is an International Non-Proprietary Name. BEMORADAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bemoradan under HS 29349990 and SITC 51579. As of Q4 2014, BEMORADAN remains the US FDA Preferred Term for this commodity. Bemoradan bears US NLM identifiers UMLS ID C0053085 and NCI Concept Code C76314. SMILES: O1C2CC(C3=NNC(=O)CC3C)CCC2NC(=O)C1.